Neftaly: Developing Financial Models for Biomarker Testing
Biomarker testing holds great promise for improving disease diagnosis, monitoring, and treatment personalization. However, the financial feasibility of implementing biomarker testing at scale—especially in diverse healthcare settings—depends on well-designed financial models that balance cost, affordability, and sustainability.
At Neftaly, we specialize in developing comprehensive financial models that guide decision-makers, investors, and health program managers in planning, budgeting, and scaling biomarker testing initiatives effectively.
Importance of Financial Models in Biomarker Testing
- Informs Investment Decisions: Clarifies the funding required across development, procurement, and operation stages.
- Ensures Sustainability: Helps forecast revenues, costs, and funding gaps for long-term program viability.
- Supports Pricing Strategies: Guides affordable pricing without compromising quality or access.
- Facilitates Resource Allocation: Enables efficient budgeting aligned with health priorities and constraints.
Neftaly’s Approach to Developing Financial Models
1. Comprehensive Cost Mapping
- Identify all cost components including test development, equipment, reagents, personnel training, quality assurance, and logistics.
- Account for fixed and variable costs, economies of scale, and potential cost fluctuations.
2. Revenue and Funding Source Analysis
- Model diverse revenue streams such as government budgets, insurance reimbursements, donor funding, and out-of-pocket payments.
- Evaluate the impact of subsidies, grants, and cost-sharing mechanisms on financial sustainability.
3. Scenario and Sensitivity Analysis
- Simulate different implementation scenarios (e.g., phased rollouts, target populations, technology variants).
- Test model robustness against uncertainties in costs, uptake rates, and reimbursement policies.
4. Integration with Health Outcomes
- Link financial inputs with expected health benefits to assess value for money.
- Incorporate cost-effectiveness data to inform budget prioritization.
5. Stakeholder Engagement and Validation
- Collaborate with policymakers, program managers, finance experts, and local stakeholders to ensure model relevance and accuracy.
- Use iterative feedback to refine assumptions and improve usability.
Example Impact
In a Neftaly project on HIV biomarker testing, the financial model:
- Mapped total costs and identified key cost drivers
- Explored pricing strategies that balanced affordability with operational sustainability
- Helped secure blended funding combining government support and donor grants
- Provided a roadmap for phased scale-up aligned with national health goals
Conclusion
Developing robust financial models is essential for the successful deployment and scaling of biomarker testing programs. Neftaly’s expertise ensures these models are tailored, data-driven, and actionable—empowering stakeholders to make informed financial decisions that maximize health impact and sustainability.